Like vincristine, we could detect an increase in priming with BAD, HRK, and MS1 BH3 peptides in CW9019 cells (Supplementary Fig. 1a) indicating that cancer cells also acquired resistance to doxorubicin treatment through BCL-xL and MCL-1. The gene discussed is HRK; the disease is cancer.